Evidence map›Paper›PMID 33335906›Full record

ArticleFrontiers in medicine2020

Case Report: A Patient With COVID-19 Who Benefited From Hemoadsorption.

Yinke Du, Zhipeng Qi, Jiangwei Ma, Da Sun, Li Yao, Bin Xu, Wei Liu, Zhaofa Xu, Yu Deng

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yinke DuDepartment of Nephrology, First Hospital of China Medical University, Shenyang, China.
Zhipeng QiDepartment of Environmental Health, School of Public Health, China Medical University, Shenyang, China.
Jiangwei MaDepartment of Pulmonary and Critical Care Medicine, First Hospital of China Medical University, Shenyang, China.
Da SunDepartment of Nephrology, First Hospital of China Medical University, Shenyang, China.
Li YaoDepartment of Nephrology, First Hospital of China Medical University, Shenyang, China.
Bin XuDepartment of Environmental Health, School of Public Health, China Medical University, Shenyang, China.
Wei LiuDepartment of Environmental Health, School of Public Health, China Medical University, Shenyang, China.
Zhaofa XuDepartment of Environmental Health, School of Public Health, China Medical University, Shenyang, China.
Yu DengDepartment of Environmental Health, School of Public Health, China Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In December 2019, the 2019 novel coronavirus disease (COVID-19), which has been identified to be caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China and spread across the world. Higher plasma levels of cytokines, including interleukin (IL)-6, IL-2, IL-7, IL-10, and tumor necrosis factor-α, were found in patients with COVID-19, which implies the occurrence of a cytokine storm and its association with disease severity. Extracorporeal blood purification has been proven to effectively remove the released inflammatory cytokines. In this study, we report on a patient with COVID-19 who benefited from hemoadsorption.

Indexed as

2019-nCoVCOVID-19epidemicextracorporeal blood purificationtreatment

Identifiers

PMID33335906
PMCPMC7736073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.